Kidney cancer: open trials in South Korea

• NCT04198766

  Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

  Trial Treatment · Phase 1/2 · Inhibrx Biosciences, Inc

  Inje University College of Medicine, Busan · Chungbuk National University Hospital, Cheongju-si · The Catholic University of Korea St. Vincent's Hospital, Gyeonggi-do · Chonnam National University Hwasun Hospital, Hwasun · Gachon University Gil Medical Center, Incheon · CHA Bundang Medical Center, Seongnam-si · Hanyang University Seoul Hospital, Seoul · Korea University Anam Hospital, Seoul · Asan Medical Center, Seoul · Korea University Guro Hospital, Seoul · The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul · Severance Hospital, Yonsei University Health System, Seoul · Ajou University Hospital, Suwon

  Registry updated 2026-11-06

• NCT03972657

  A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

  Trial Treatment · Phase 1/2 · Regeneron Pharmaceuticals

  Yonsei University - Severance Hospital - Colorectal Cancer Clinic, Seoul · Asan Medical Center, Seoul · The Catholic University of Korea - St. Vincent's Hospital - Lung Cancer Center, Suwon

  Registry updated 2026-11-04

• NCT05536141

  A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

  Trial Treatment · Phase 1 · Arcus Biosciences, Inc.

  Seoul

  Registry updated 2026-11-02

• NCT07011719

  Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

  Trial Treatment · Phase 3 · Arcus Biosciences, Inc.

  Busan · Daejeon · Goyang · Seongnam · Seoul · Suwon

  Registry updated 2026-11-02

• NCT07489495

  A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

  Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC

  Severance Hospital, Yonsei University Health System (Site 2903), Seoul · Asan Medical Center (Site 2901), Seoul · Samsung Medical Center (Site 2902), Seoul

  Registry updated 2026-10-29

• NCT07049926

  Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

  Trial Treatment · Phase 1/2 · Merck Sharp & Dohme LLC

  Samsung Medical Center (Site 5801), Seoul · Asan Medical Center (Site 5800), Seoul · Severance Hospital (Site 5802), Seoul

  Registry updated 2026-10-27

• NCT07293351

  A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

  Trial Treatment · Phase 1/2 · Bristol-Myers Squibb

  Asan Medical Center, Seoul · Severance Hospital, Yonsei University Health System, Seoul · Samsung Medical Center, Seoul

  Registry updated 2026-10-23

• NCT04977453

  GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

  Trial Treatment · Phase 1/2 · GI Innovation, Inc.

  Chungnam National University Hospital, Daejeon · Ewha Womans University Mokdong Hospital, Seoul · Seoul National University Bundang Hospital, Seoul · Yonsei University Health System, Severance Hospital, Seoul · Asan Medical Center, Seoul · Korea University Anam Hospital, Seoul · The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul · Samsung Medical Center, Seoul · The Catholic University of Korea St. Vincent's Hospital, Suwon

  Registry updated 2026-10-19

• NCT07115043

  A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

  Trial Treatment · Phase 1/2 · AstraZeneca

  Seoul

  Registry updated 2026-10-08

• NCT07172802

  A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors

  Trial Treatment · Phase 1/2 · GI Innovation, Inc.

  Yonsei University Health System, Severance Hospital, Seoul · Samsung Medical Center, Seoul · Asan Medical Center, Seoul

  Registry updated 2026-09-17

• NCT07227402

  A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

  Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC

  Chonnam National University Hwasun Hospital (Site 2505), Hwasun-gun · Seoul National University Bundang Hospital (Site 2504), Seongnam · Severance Hospital, Yonsei University Health System (Site 2503), Seoul · Samsung Medical Center (Site 2502), Seoul · Asan Medical Center (Site 2501), Seoul · Chungnam National University Hospital (Site 2506), Taejŏn

  Registry updated 2026-08-03

• NCT04777994

  Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

  Trial Treatment · Phase 1 · Calico Life Sciences LLC

  Samsung Medical Center /ID# 260664, Seoul · Yonsei University Health System Severance Hospital /ID# 260665, Seoul · Seoul National University Hospital /ID# 254635, Seoul

  Registry updated 2026-06-04

• NCT07469683

  An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma

  Trial Treatment · Phase 2 · Yonsei University

  Severance hospital, Seoul

  Registry updated 2026-03-13

• NCT06945640

  Evaluation of 'RUS NE' in Robot-Assisted Partial Nephrectomy: Efficacy, Safety, and Stability

  Trial Treatment · Hutom Corp

  Asan Medical Center, Seoul

  Registry updated 2025-09-16

• NCT06868186

  A Multicenter Study of RUS NE

  Trial Treatment · Hutom Corp

  Chonnam National University Hospital, Kwangju · Severance hospital, Seoul · Samsung Medical Center, Seoul · Asan Medical Center, Seoul

  Registry updated 2025-09-11

• NCT03592472

  A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

  Trial Treatment · Phase 3 · Xynomic Pharmaceuticals, Inc.

  National Cancer Center - Center For Prostate Cancer, Goyang-si · CHA Bundang Medical Center, CHA University, Seongnam-si · Samsung Medical Center - Hematology & Oncology, Seoul · Asan Medical Center - University of Ulsan College of Medicin, Seoul · Severance Hospital, Yonsei University Health System - Medical Oncology, Seoul

  Registry updated 2025-04-13

• NCT05824975

  A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

  Trial Treatment · Phase 1/2 · GI Innovation, Inc.

  Seoul National University Hospital, Seoul · Yonsei University Health System, Severance Hospital, Seoul · Samsung Medical Center, Seoul · Asan Medical Center, Seoul · St. Vincent's Hospital, Suwon

  Registry updated 2024-11-25

• NCT06467097

  Systemic Treatment Alone Versus Systemic Treatment Plus Radiotherapy in Oligometastatic Renal Cell Carcinoma

  Trial Treatment · Phase 3 · Samsung Medical Center

  Samsung Medical Center, Seoul

  Registry updated 2024-06-20

• NCT06265025

  GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors

  Trial Treatment · Phase 1/2 · GeneMedicine Co., Ltd.

  National Cancer Center, Goyang-si · Korea University Anam Hospital, Seoul · Hanyang University Seoul Hospital, Seoul · Severance Hospital, Yonsei University Health System, Seoul

  Registry updated 2024-03-21

• NCT05753839

  The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma in Immuno-oncology Era: SEVURO-CN Trial

  Trial Treatment · Yonsei University

  Gangnam Severance Hospital, Seoul · Yonsei University Health System, Severance Hospital, Seoul · Yongin Severance Hospital, Yongin-si

  Registry updated 2023-06-22

• NCT04625556

  Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome

  Research · Yonsei University

  Yonsei Severance Hospital, Seoul

  Registry updated 2023-01-31

• NCT04197414

  Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA

  Research · Yonsei University

  Department of Urology, Urological Science Institute, Yonsei University, Colleage of Medicine, Seoul

  Registry updated 2019-12-13

All Kidney cancer trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error